p66 - pituitary adenylate cyclase-activating peptide analog

a 31 amino acid pituitary adenylate cyclase-activating peptide analog formulated in several non-aqueous solvents in anticipation of improved shelf-life stability

Also Known As:

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Claus, Thomas H: 1 article (02/2007)
2.	Dumas, Michael: 1 article (02/2007)
3.	Froland, Wayne: 1 article (02/2007)
4.	Li, Fugang: 1 article (02/2007)
5.	Li, Yaxin: 1 article (02/2007)
6.	Pan, Clark Q: 1 article (02/2007)
7.	Roczniak, Steve: 1 article (02/2007)
8.	Tom, Irene: 1 article (02/2007)
9.	Wang, Wei: 1 article (02/2007)
10.	Wang, Y John: 1 article (02/2007)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 02/01/2007 - "A previously described VPAC2-selective agonist, BAY 55-9837 (peptide HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY), had several limitations with respect to its potential as an insulin secretagogue for the treatment of type 2 diabetes. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Insulin (Novolin)
3.	Secretagogues
4.	Lys(15)-Arg(16)-Leu(27)- vasoactive intestinal peptide (1-7)-GRF (8-27)